These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

119 related articles for article (PubMed ID: 33295411)

  • 1. Infliximab-induced remission improves physical activity in patients with active Crohn's disease.
    Lucca FA; Malaguti C; Chebli LA; Reboredo MM; Pinheiro BV; Ribeiro TCDR; Azevedo FM; Corrêa JODA; Gaburri PD; Chebli JMF
    Rev Assoc Med Bras (1992); 2020 Nov; 66(11):1566-1572. PubMed ID: 33295411
    [TBL] [Abstract][Full Text] [Related]  

  • 2. PHYSICAL ACTIVITY IN DAILY LIFE, EXERCISE CAPACITY AND QUALITY OF LIFE IN PATIENTS WITH CROHN'S DISEASE ON INFLIXIMAB-INDUCED REMISSION: A PRELIMINARY STUDY.
    Cabalzar AL; Azevedo FM; Lucca FA; Reboredo MM; Malaguti C; Chebli JMF
    Arq Gastroenterol; 2019; 56(4):351-356. PubMed ID: 31618395
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Infliximab heals intestinal inflammatory lesions and restores growth in children with Crohn's disease.
    Borrelli O; Bascietto C; Viola F; Bueno de Mesquita M; Barbato M; Mancini V; Bosco S; Cucchiara S
    Dig Liver Dis; 2004 May; 36(5):342-7. PubMed ID: 15191204
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Increases in body mass index during infliximab therapy in patients with Crohn's disease: an open label prospective study.
    Nakahigashi M; Yamamoto T
    Cytokine; 2011 Nov; 56(2):531-5. PubMed ID: 21820319
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Efficacy and Safety of Infliximab Therapy and Predictors of Response in Korean Patients with Crohn's Disease: A Nationwide, Multicenter Study.
    Choi CH; Song ID; Kim YH; Koo JS; Kim YS; Kim JS; Kim N; Kim ES; Kim JH; Kim JW; Kim TO; Kim HS; Kim HJ; Park YS; Park DI; Park SJ; Song HJ; Shin SJ; Yang SK; Ye BD; Lee KM; Lee BI; Lee SY; Lee CK; Im JP; Jang BI; Jeon TJ; Cho YK; Chang SK; Jeon SR; Jung SA; Jeen YT; Cha JM; Han DS; Kim WH;
    Yonsei Med J; 2016 Nov; 57(6):1376-85. PubMed ID: 27593865
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Evaluation of the infliximab therapy of severe form of pediatric Crohn's disease in Poland: Retrospective, multicenter studies.
    Iwańczak BM; Ryżko J; Jankowski P; Sładek M; Wasilewska A; Szczepanik M; Sienkiewicz E; Szaflarska-Popławska A; Więcek S; Czaja-Bulsa G; Korczowski B; Maślana J; Iwańczak F; Kacperska M
    Adv Clin Exp Med; 2017; 26(1):51-56. PubMed ID: 28397432
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Increasing Infliximab Dose Based on Symptoms, Biomarkers, and Serum Drug Concentrations Does Not Increase Clinical, Endoscopic, and Corticosteroid-Free Remission in Patients With Active Luminal Crohn's Disease.
    D'Haens G; Vermeire S; Lambrecht G; Baert F; Bossuyt P; Pariente B; Buisson A; Bouhnik Y; Filippi J; Vander Woude J; Van Hootegem P; Moreau J; Louis E; Franchimont D; De Vos M; Mana F; Peyrin-Biroulet L; Brixi H; Allez M; Caenepeel P; Aubourg A; Oldenburg B; Pierik M; Gils A; Chevret S; Laharie D;
    Gastroenterology; 2018 Apr; 154(5):1343-1351.e1. PubMed ID: 29317275
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Randomised clinical trial: deep remission in biologic and immunomodulator naïve patients with Crohn's disease - a SONIC post hoc analysis.
    Colombel JF; Reinisch W; Mantzaris GJ; Kornbluth A; Rutgeerts P; Tang KL; Oortwijn A; Bevelander GS; Cornillie FJ; Sandborn WJ
    Aliment Pharmacol Ther; 2015 Apr; 41(8):734-46. PubMed ID: 25728587
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Infliximab: an updated review of its use in Crohn's disease and rheumatoid arthritis.
    Keating GM; Perry CM
    BioDrugs; 2002; 16(2):111-48. PubMed ID: 11985485
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Association Between Serum Infliximab Trough Concentrations During Maintenance Therapy and Biochemical, Endoscopic, and Histologic Remission in Crohn's Disease.
    Papamichael K; Rakowsky S; Rivera C; Cheifetz AS; Osterman MT
    Inflamm Bowel Dis; 2018 Sep; 24(10):2266-2271. PubMed ID: 29718327
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Circulating Interleukin 6 and Albumin, and Infliximab Levels Are Good Predictors of Recovering Efficacy After Dose Escalation Infliximab Therapy in Patients with Loss of Response to Treatment for Crohn's Disease: A Prospective Clinical Trial.
    Suzuki Y; Matsui T; Ito H; Ashida T; Nakamura S; Motoya S; Matsumoto T; Sato N; Ozaki K; Watanabe M; Hibi T
    Inflamm Bowel Dis; 2015 Sep; 21(9):2114-22. PubMed ID: 26218144
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Infliximab in treatment of Crohn's disease: the Milan experience.
    Ardizzone S; Colombo E; Maconi G; Bollani S; Manzionna G; Petrone MC; Bianchi Porro G
    Dig Liver Dis; 2002 Jun; 34(6):411-8. PubMed ID: 12132788
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Adrenomedullin: A Novel Therapy for Intractable Crohn's Disease with a Loss of Response to Infliximab.
    Ashizuka S; Kuroishi N; Nakashima K; Inatsu H; Kita T; Kitamura K
    Intern Med; 2019 Jun; 58(11):1573-1576. PubMed ID: 30713309
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Combining infliximab with methotrexate for the induction and maintenance of remission in refractory Crohn's disease: a controlled pilot study.
    Schröder O; Blumenstein I; Stein J
    Eur J Gastroenterol Hepatol; 2006 Jan; 18(1):11-6. PubMed ID: 16357613
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Number needed to treat and cost per remitter for biologic treatments of Crohn's disease in Japan.
    Ueno F; Doi M; Kawai Y; Ukawa N; Cammarota J; Betts KA
    J Med Econ; 2020 Jan; 23(1):80-85. PubMed ID: 31294641
    [No Abstract]   [Full Text] [Related]  

  • 16. Retrieval of serum infliximab level by shortening the maintenance infusion interval is correlated with clinical efficacy in Crohn's disease.
    Hibi T; Sakuraba A; Watanabe M; Motoya S; Ito H; Motegi K; Kinouchi Y; Takazoe M; Suzuki Y; Matsumoto T; Kawakami K; Matsumoto T; Hirata I; Tanaka S; Ashida T; Matsui T
    Inflamm Bowel Dis; 2012 Aug; 18(8):1480-7. PubMed ID: 21987418
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Comparative Effectiveness of Infliximab Versus Adalimumab in Patients with Biologic-Naïve Crohn's Disease.
    Benmassaoud A; Al-Taweel T; Sasson MS; Moza D; Strohl M; Kopylov U; Paradis-Surprenant L; Almaimani M; Bitton A; Afif W; Lakatos PL; Bessissow T
    Dig Dis Sci; 2018 May; 63(5):1302-1310. PubMed ID: 29243105
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Mean Platelet Volume in Crohn's Disease Patients Predicts Sustained Response to a 52-Week Infliximab Therapy: A Pilot Study.
    Sobolewska A; Włodarczyk M; Stec-Michalska K; Fichna J; Wiśniewska-Jarosińska M
    Dig Dis Sci; 2016 Feb; 61(2):542-9. PubMed ID: 26441277
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Serum concentrations after switching from originator infliximab to the biosimilar CT-P13 in patients with quiescent inflammatory bowel disease (SECURE): an open-label, multicentre, phase 4 non-inferiority trial.
    Strik AS; van de Vrie W; Bloemsaat-Minekus JPJ; Nurmohamed M; Bossuyt PJJ; Bodelier A; Rispens T; van Megen YJB; D'Haens GR;
    Lancet Gastroenterol Hepatol; 2018 Jun; 3(6):404-412. PubMed ID: 29606564
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Monotherapy with infliximab versus combination therapy in the maintenance of clinical remission in children with moderate to severe Crohn disease.
    Kierkuś J; Iwańczak B; Wegner A; Dadalski M; Grzybowska-Chlebowczyk U; Łazowska I; Maślana J; Toporowska-Kowalska E; Czaja-Bulsa G; Mierzwa G; Korczowski B; Czkwianianc E; Żabka A; Szymańska E; Krzesiek E; Więcek S; Sładek M
    J Pediatr Gastroenterol Nutr; 2015 May; 60(5):580-5. PubMed ID: 25564804
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.